SecBot SecBot
8-K ·Filed Jun 8, 2026

TNGX

Tango Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001193125-26-260679
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The data are a major positive catalyst for TNGX, validating the PRMT5 + RAS(ON) combination strategy in pancreatic cancer. Traders should watch for: (1) regulatory feedback on Phase 3 design in 2H 2026, (2) upcoming vopimetostat monotherapy data in lung cancer and TNG456 GBM data in 2H 2026, and (3) potential partnership or licensing interest given the strong efficacy signal. The $380M cash runway into 2028 provides financial flexibility to execute on the Phase 3 plan without near-term dilution risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.93
T+0 close · Jun 8, 2026 · via day close
Latest settled
−27.74%
T+60 · $22.35
Vs SPY
−30.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $30.93entry
  2. T+1 · 5mo ago +2.04%α +2.33% · $31.56
  3. T+5 · 5mo ago +6.37%α +4.26% · $32.90
  4. T+20 · 4mo ago −3.20%α −4.83% · $29.94
  5. T+60 · 3mo ago −27.74%α −30.79% · $22.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted, RAS-mutant pancreatic cancer. The vopimetostat + daraxonrasib arm showed a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in 12 evaluable second/third-line PDAC patients, with a manageable safety profile. The company plans to rapidly advance this combination into a Phase 3 randomized-controlled trial in front-line pancreatic cancer, subject to regulatory feedback.

Key Facts

  • Vopimetostat + daraxonrasib in 2/3L PDAC: 92% ORR (11/12 patients; 9 confirmed), 90% 6-month PFS rate, 100% DCR.
  • Vopimetostat + zoldonrasib in 2/3L PDAC: 52% ORR (14/27; 10 confirmed), 74% 6-month PFS rate, 96% DCR.
  • Combined ORR across both arms in PDAC: 64% (25/39 patients).
  • No discontinuations due to adverse events in either combination arm; no related Grade 4/5 AEs.
  • Company intends to initiate a Phase 3 randomized-controlled trial in front-line PDAC in 2H 2026.
  • $380M cash and investments as of March 31, 2026; cash runway into 2028.
  • Data as of May 28, 2026 cutoff; median follow-up 6.3 months (range 3.3-11.1) for combined PDAC arms.

Financial Impact

Transformative clinical data for vopimetostat in pancreatic cancer, a large unmet need (~40% of PDAC patients are MTAP-deleted). The 92% ORR in 2/3L PDAC with daraxonrasib is unprecedented and supports a potential blockbuster opportunity. No financial figures from the filing to quantify deal value or revenue impact.

pipeline valueclinical trial outcomescash runway

Risk Factors

  • Early-stage data (n=12 evaluable for daraxonrasib arm) may not replicate in larger, randomized trials.
  • Competition from other PRMT5 inhibitors and RAS-targeted therapies in development.
  • Regulatory path for accelerated approval is uncertain and subject to FDA feedback.
  • Dependence on Revolution Medicines for supply of daraxonrasib and zoldonrasib.
  • Clinical trial execution risk for the planned Phase 3 study.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-260679
Document: d158334d8k.htm0001193125-26-260679
Document: d158334dex991.htm0001193125-26-260679
Document: 0001193125-26-260679-index-headers.html0001193125-26-260679
Document: 0001193125-26-260679-index.html0001193125-26-260679
Document: 0001193125-26-260679.txt0001193125-26-260679

Track record

27 reports on TNGX

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026